Amycretin data highlight supply challenges for oral peptides in obesity

The oral obesity candidate that has shown the best efficacy to date is also unlikely to ever reach the commercial market, and it is not because of any major safety concerns. The most probable reason: constraints in peptide manufacturing capacity. 

On Wednesday, Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) presented additional details from its Phase I study of oral amycretin, a co-agonist of amylin and GLP-1 that showed up to 12% placebo-adjusted weight loss after 12 weeks in a 124-patient trial. Data were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Madrid, Spain...